We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Feasibility Study on Stem Cells Sensitivity Assay (STELLA)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 1, 2011
Last Update Posted: January 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Associazione Oncologia Traslazionale

Lung Cancer (LC), colorectal cancer (CRC) and breast cancer (BC) are the major killers in oncology, accounting for about 40% of cancer deaths. Although progresses have been made in the last few years, unfortunately no patient with metastatic disease can obtain a definitive cure.

A recent hypothesis is that cancer is driven by a small subpopulation of cells called "cancer stem cells" (CSCs) or "tumor initiating cells" with an unlimited proliferative potential and the ability to reproduce the original human tumor in experimental animal models. These cells are thought to be responsible for the development of the tumor and represent the only cell population able to sustain tumor growth and progression.

Therefore, CSCs represent the elective target for new targeted therapies, endowed with high and selective toxicity towards the tumor but harmless towards normal cells.

Current technologies allow us to isolate and expand in vitro the CSCs from tumor specimens, testing their sensitivity to different anticancer drugs in a short period of time.

Therefore, there is the potential opportunity to identify LC, CRC and BC CSCs.This is a prospective study assessing feasibility of CSCS isolation in LC, CRC and BC.

Patients with a previously performed diagnosis of LC, colon cancer or breast cancer with no further standard therapy options, with a Karnofsky performance status of 100% and with tumor tissue available will be considered eligible for the study. Tumor tissue will be collected before study entry, i.e tissue obtained during a diagnostic or therapeutical procedure, like surgery or biopsies with other purposes than the protocol. In vitro tumor sensitivity to chemotherapy drugs will be tested on tumor cell cultures per each patient.

Drugs and their combination will be considered effective and if they kill ≥ 60% of tumor stem cells in vitro test. By using cancer spheres the investigators will also generate orthotopic xenograft models that recapitulate the parental tumor behaviour, including the aggressive features and the invasiveness potential. Orthotopic injection technique will be assessed in 5 weeks-old NOD/SCID mice

Condition Intervention Phase
Lung Cancer Colorectal Cancer Breast Cancer Drug: Cancer Stem Cells Sensitivity Assay Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: STELLA: a Feasibility Study on Stem Cells Sensitivity Assay

Resource links provided by NLM:

Further study details as provided by Associazione Oncologia Traslazionale:

Primary Outcome Measures:
  • Feasibility of the project [ Time Frame: 6 Months ]
    Percentage of patients in which sensitivity assay is feasible

Secondary Outcome Measures:
  • Identification of LC, CRC and BC stem cells [ Time Frame: 6 Months ]
    Identification of breast, colo-rectal and lung cancer stem cells by flow cytometric analysis or immunofluorescence

  • Sensitivity of LC, CRC and BC stem cells to anti-tumor agents in vitro [ Time Frame: 6 Months ]
    In vitro tumor sensitivity to chemotherapy drugs will be tested on tumor cell cultures per each patient.

  • Identification of effective drugs for a specific patient [ Time Frame: 6 months ]
    To identify drugs potentially effective for a specific patient

Enrollment: 23
Study Start Date: November 2011
Study Completion Date: December 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sensitivity Assay
Patients treated with a treatment chosen by sensitivity assay in vitro
Drug: Cancer Stem Cells Sensitivity Assay
To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
Other Name: Cancer stem cells in vitro chemo-sensitivity assay

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically/cytologically confirmed diagnosis of metastatic LC, CRC or BC
  • Availability of tumor tissue suitable for CSCs extraction
  • Performance status of 100% according to Karnofsky score
  • Failure of conventional therapies or no therapy of proven efficacy
  • Adequate hematological, renal and liver functions
  • No concomitant comorbidity potentially interfering with the study
  • Informed consent form signature.

Exclusion Criteria:

  • Performance status <100% according to Karnofsky score
  • Patient suitable for standard therapies
  • Important comorbidity interfering with the study
  • Significant alteration of liver, hematological or renal function(s)
  • No informed consent form signature
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01483001

Department of Medical Oncology
Livorno, Italy, 57100
Sponsors and Collaborators
Associazione Oncologia Traslazionale
Principal Investigator: FEDERICO CAPPUZZO, ONCOLOGY A.O.T.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Associazione Oncologia Traslazionale
ClinicalTrials.gov Identifier: NCT01483001     History of Changes
Other Study ID Numbers: LIVONCO 2011/001
2011-003421-10 ( EudraCT Number )
First Submitted: October 27, 2011
First Posted: December 1, 2011
Last Update Posted: January 14, 2015
Last Verified: January 2015

Keywords provided by Associazione Oncologia Traslazionale:
Cancer Stem Cells
Chemo-Sensitivity Assay
Cancer Treatment

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Immune System Diseases